Connective Tissue Diseases: Clinical Trials

1,003 trials for Connective Tissue Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

538 completed, 164 recruiting, 90 terminated, 70 unknown. 1003 Phase 1, 311 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11003Completed 538, Recruiting 164, Terminated 90, Unknown 70, Not yet recruiting 47, Withdrawn 42, Active not recruiting 40, Enrolling by invitation 6, Suspended 6
Phase 2311Completed 144, Recruiting 54, Unknown 30, Terminated 29, Active not recruiting 19, Not yet recruiting 17, Withdrawn 14, Enrolling by invitation 2, Suspended 2

Follow Connective Tissue Diseases: new trials by email Literature Review of Connective Tissue Diseases trials Research Report on Connective Tissue Diseases

Trials (filtered) newest first · largest first

All 1,003 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cannabichromene Safety in Rheumatoid Arthritis
Cannabichromene - Arthritis, Rheumatoid
Phase 1 / Phase 2WithdrawnCrystal Lederhos Smith2028-07-152026-09-23
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
CB-010 - Systemic Lupus Erythematosus, Lupus
Phase 1WithdrawnCaribou Biosciences, Inc.2027-12-012025-09-19
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy
C-CAR168 - Systemic Sclerosis (SSc), Systemic Sclerosis
Phase 1Not yet recruitingAbelZeta Inc.122027-03-012026-10-13
Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB
rAAV9-CMV-hNAGLUop - Sanfilippo Syndrome (MPS III)
Phase 1 / Phase 2Not yet recruitingNeuroGT92027-01-182026-09-14
Regenerative Medicine for Joint Hypermobility and Instability
Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS)
Phase 1 / Phase 2Not yet recruitingManhattan Pain Medicine, PLLC1002027-01-152026-10-06
Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)
Bone marrow-derived mesenchymal stromal cells (MSCs) - Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III
Phase 1 / Phase 2Not yet recruitingEmory University122027-01-012026-05-08
An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1
CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV)
Phase 1 / Phase 2Not yet recruitingUniversity Hospital Tuebingen362027-01-012026-11-12
Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
HN2302 Injection - Autoimmune Disease, Systemic Lupus Erythematosus
Phase 1Not yet recruitingShenzhen MagicRNA Biotechnology Co., Ltd122026-12-312026-08-12
Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases
anti-CD19 CAR-T cells - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
Phase 1Not yet recruitingGustave Roussy, Cancer Campus, Grand Paris62026-12-012026-09-02
Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma
Phase 1Not yet recruitingJonsson Comprehensive Cancer Center182026-12-012026-08-06
Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis
hUC-MSC suspension, Placebo - Rheumatoid Arthritis
Phase 1Not yet recruitingBaylx Inc.162026-12-012025-12-23
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
DKB903 - Rheumatoid Arthritis and Systemic Lupus Erythematosus
Phase 1Not yet recruitingNovartis Pharmaceuticals902026-12-012026-11-06
A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases
QLS2416 Injection - Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA)
Phase 1Not yet recruitingShanghai Qilu Pharmaceutical Research and Development Center LTD762026-12-012026-10-30
A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases
PF-08154225 - Systemic Lupus Erythematosus, Rheumatoid Arthritis
Phase 1 / Phase 2Not yet recruitingPfizer542026-11-192026-10-01
A Study to Evaluate the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic Lupus Erythematosus Who Are Administered Dapirolizumab Pegol
Dapirolizumab pegol (DZP) - Systemic Lupus Erythematosus
Phase 1Not yet recruitingUCB Biopharma SRL252026-11-152026-11-13
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Cevostamab, Tocilizumab - Lupus Erythematosus, Systemic
Phase 1RecruitingGenentech, Inc.462026-11-022026-11-05
Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Phase 1 / Phase 2Not yet recruitingPeking University Third Hospital92026-11-012026-09-23
R-2487 in Patients With Sjogren's Syndrome (SjD)
R-2487 - Sjogren's Syndrome, Sjögren
Phase 1Not yet recruitingRise Therapeutics LLC362026-11-012026-11-06
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease
Phase 1Not yet recruitingBristol-Myers Squibb602026-10-302026-10-14
Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)
Anifrolumab: SC formulation via AI, Anifrolumab: IV formulation, Anifrolumab: SC formulation via aPFS - Systemic Lupus Erythematosus
Phase 1Not yet recruitingAstraZeneca922026-10-302026-07-07

Showing 20 of 1003. Sign in to see all of them.

Narrower conditions

Arthritis, Rheumatoid (386)  ·  Lupus Erythematosus, Systemic (288)  ·  Scleroderma, Systemic (107)  ·  Lupus Nephritis (71)  ·  Autoimmune Diseases (61)  ·  Scleroderma, Diffuse (48)  ·  Sjogren's Syndrome (45)  ·  Myositis (39)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (29)  ·  Dermatomyositis (29)  ·  Mucopolysaccharidosis I (28)  ·  Arthritis (26)  ·  Epidermolysis Bullosa Dystrophica (25)  ·  Arthritis, Juvenile (24)  ·  Inflammation (21)

Broader conditions

Skin and Connective Tissue Diseases (999)  ·  Immune System Diseases (721)  ·  Autoimmune Diseases (660)  ·  Musculoskeletal Diseases (520)  ·  Joint Diseases (452)  ·  Rheumatic Diseases (445)  ·  Arthritis (432)  ·  Skin Diseases (237)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (146)  ·  Genetic Diseases, Inborn (123)  ·  Nervous System Diseases (111)  ·  Pathological Conditions, Signs and Symptoms (107)  ·  Nutritional and Metabolic Diseases (91)  ·  Pathologic Processes (91)

Interventions

Cyclophosphamide (35)  ·  fludarabine (29)  ·  Methotrexate (25)  ·  Rituximab (19)  ·  tocilizumab (17)  ·  Abatacept (16)  ·  tofacitinib (14)  ·  sarilumab (12)  ·  belimumab (9)  ·  Etanercept (7)  ·  Saline Solution (7)  ·  fostamatinib (7)  ·  Iduronidase (6)  ·  Injections (6)  ·  Midazolam (6)

Sponsors

GlaxoSmithKline (31)  ·  Bristol-Myers Squibb (29)  ·  Pfizer (26)  ·  Amgen (25)  ·  AstraZeneca (23)  ·  Novartis Pharmaceuticals (17)  ·  Sanofi (12)  ·  Eli Lilly and Company (11)  ·  Hoffmann-La Roche (10)  ·  Novo Nordisk A/S (10)  ·  National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (9)  ·  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (9)  ·  Chongqing Precision Biotech Co., Ltd (8)  ·  Gilead Sciences (8)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (8)

Countries

United States (450)  ·  China (173)  ·  Germany (94)  ·  United Kingdom (75)  ·  Spain (73)  ·  Australia (51)  ·  France (49)  ·  Poland (47)  ·  Canada (43)  ·  Netherlands (41)  ·  South Korea (40)  ·  Japan (34)  ·  Belgium (28)  ·  Italy (28)  ·  Russia (26)

Top investigators

Qiubai Li, Professor (6)

Results publications

PMID 34628605, PMID 34741731, PMID 22547151, PMID 25421091, PMID 25749867, PMID 26138472, PMID 26290435, PMID 27099766, PMID 27112532, PMID 28143815, PMID 28925994, PMID 29526614, PMID 29776017, PMID 29976218, PMID 32453485, PMID 32816215, PMID 33127856, PMID 33506875, PMID 33687069, PMID 34347960, PMID 34870800, PMID 35835061, PMID 36109639, PMID 36299240, PMID 36526796, PMID 36600185, PMID 36601090, PMID 36931693, PMID 38258274, PMID 39454617, PMID 10415784, PMID 15324318, PMID 15807196, PMID 17425783, PMID 18250115, PMID 18459515, PMID 18468955, PMID 18534016, PMID 18759293, PMID 18786258, PMID 18986773, PMID 19146602, PMID 19180499, PMID 19208097, PMID 19273451, PMID 19587341, PMID 19948615, PMID 19950289, PMID 20112381, PMID 20131246

NIH funding

2015 (14), 2017 (12), 2023 (10), 2025 (10), 2009 (7), 2016 (6), 2008 (5), 2014 (5), 2018 (4), 2019 (4), R01AR056702 (2), 2004 (1), K23AR002187 (1), K23AR075874 (1), P01HL075462 (1)